Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: A systematic review and network meta-analysis
Publication Details
Hazelwood, G. S.,
Whittle, S. L.,
Kamso, M. M.,
Akl, E. A.,
Wells, G. A.,
Tugwell, P.,
Thomas, M.,
Lee, C.,
Ejaredar, M.,
Choudhary, D.,
Neuen, D. R.,
New-Tolley, J.,
Powell, M.,
Quinlivan, A.,
Qaddoura, A.,
Pearson, R.,
Maxwell, L. J.,
Pardo, J. P.,
Kelly, S.,
&
Buchbinder, R.
(2020).
Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: A systematic review and network meta-analysis.
Cochrane Database of Systematic Reviews, 2020 (3).
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The primary objective is to compare the benefits and harms of different disease‐modifying anti‐rheumatic drugs (DMARDs) as initial therapy and after failure of conventional synthetic DMARDs or biologic or targeted synthetic DMARDs in adults with rheumatoid arthritis through a network meta‐analysis (NMA). A secondary objective is to rank the interventions for both benefits and harms.
This protocol describes the approach for separate NMAs for the three populations of interest (described below), which we intend to publish as three separate Cochrane Reviews.
1) Disease‐modifying anti‐rheumatic drugs for rheumatoid arthritis as initial therapy: a systematic review and network meta‐analysis
2) Disease‐modifying anti‐rheumatic drugs for rheumatoid arthritis after failure of conventional synthetic disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis
3) Disease‐modifying anti‐rheumatic drugs for rheumatoid arthritis after failure of biologic or targeted synthetic therapy: a systematic review and network meta‐analysis
Keywords
protocol, network meta‐analysis (NMA), anti‐rheumatic drugs (DMARDs), adults, rheumatoid arthritis
Link to Publisher Version (URL)
